Last reviewed · How we verify

NCT07207564

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

Recruiting now Last updated 13 March 2026
What this trial tests

trial testing Non-Interventional Study in Breast Carcinoma in 4,500 participants. Currently enrolling.

Timeline
28 August 2025
Primary endpoint
30 June 2030
30 June 2030

Quick facts

Lead sponsorMayo Clinic
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment4,500
Start date28 August 2025
Primary completion30 June 2030
Estimated completion30 June 2030
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Adults 18 to 100, female only, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to better understand how benign breast diseases might lead to breast cancer, focusing on genetic factors and including a diverse range of participants to improve future diagnosis and treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07207564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing